EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis

Richard Furie, Hans-Joachim Anders, George Bertsias, Ana Delgado, Roger A Levy, Paula Curtis, Ciara O'Shea, Ryan Tomlinson, Brad Rovin

Kidney International · 2026-08 · 110 (2) · 451-462

DOI: 10.1016/j.kint.2026.03.030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2026-08. Verfasst von Richard Furie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lupus Nephritis, Mycophenolic Acid, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline, American Society of Nephrology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Belimumab, approved for systemic lupus erythematosus (SLE) and lupus nephritis (LN) treatment, is a B-cell-modulating monoclonal antibody that selectively inhibits B-lymphocyte stimulator (BLyS) and downregulates autoreactive B-cells. Comparing belimumab's results from BLISS-LN (phase 3, ClinicalTrials.gov Identifier: NCT01639339) with other LN trial outcomes pose challenges because, unlike other trials, BLISS-LN included patients with pure class V LN (membranous) and patients receiving cyclophosphamide as standard therapy (ST). This post hoc analysis of BLISS-LN investigated kidney outcomes in patients with proliferative (class III or IV) or proliferative plus membranous LN (class III or IV with/without class V) treated with mycophenolate mofetil (MMF)-based ST to more closely align with those of other phase 3 LN trials and current practice. METHODS: Only patients with active class III or IV LN with/without class V who received MMF ST in BLISS-LN were included. Kidney responses (complete renal response [CRR]; primary efficacy renal response [PERR]), urine protein to creatinine ratio (uPCR) under 0.5 g/g responders, estimated glomerular filtration rate (eGFR) slope, and changes from baseline in uPCR, eGFR, and biomarkers were assessed up to Week 104. Safety outcomes were assessed through Week 104. RESULTS: The MMF subgroup comprised 271 patients (60.5% of overall BLISS-LN population; with 135 receiving belimumab; 136 receiving placebo). Baseline demographics and characteristics were balanced. CRR treatment differences between belimumab and placebo were higher in the MMF subgroup (14.9%) versus the overall BLISS-LN population (10.3%). Treatment differences were greater for PERR, uPCR under 0.5 responders and eGFR slope with belimumab versus placebo in the MMF subgroup, and versus the overall population. Other endpoints showed a similar trend. Safety outcomes were consistent with belimumab's known safety profile. Fewer serious adverse events were reported for belimumab vs placebo in the MMF subgroup. CONCLUSIONS: The improvements in kidney outcomes with belimumab in patients with LN receiving MMF highlight the benefit of belimumab in a population more closely aligned with recent phase 3 LN trials and underlines kidney function preservation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLupus NephritisMycophenolic AcidImmunosuppressive AgentsKidneyHumansFemaleAdultTreatment OutcomeDrug Therapy, CombinationMaleCyclophosphamideGlomerular Filtration RateMiddle AgedProteinuriaRemission InductionB-Cell Activating FactorCreatinineDouble-Blind Method

Stichwörter der Autor:innen

BLISS-LN subgroup analysisbelimumablupus nephritisphase 3 trial

Substanzen

belimumabAntibodies, Monoclonal, HumanizedMycophenolic AcidImmunosuppressive AgentsCyclophosphamideB-Cell Activating FactorCreatinine

Autor:innen und Institutionen

  • Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.
  • Department of Medicine IV, Hospital of Ludwig-Maximilian-University Munich, Munich, Germany.
  • Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece.
  • Immunology Medical Affairs, GSK, London, UK.
  • Specialty Care, Global Medical Affairs, GSK, Collegeville, Pennsylvania, USA. Electronic address: roger.x.levy@gsk.com.
  • Statistics, GSK, London, UK.

Förderung

  • GlaxoSmithKline
  • American Society of Nephrology

Zitieren

APA

Furie, R., Anders, H. J., Bertsias, G., Delgado, A., Levy, R. A., Curtis, P., O'Shea, C., Tomlinson, R., & Rovin, B. (2026). A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis. Kidney International, 110(2), 451-462. https://doi.org/10.1016/j.kint.2026.03.030

Vancouver

Furie R, Anders HJ, Bertsias G, Delgado A, Levy RA, Curtis P, et al. A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis. Kidney International. 2026;110(2):451-462. doi:10.1016/j.kint.2026.03.030

BibTeX
@article{Furie2026,
  author = {Furie, Richard and Anders, Hans-Joachim and Bertsias, George and Delgado, Ana and Levy, Roger A and Curtis, Paula and O'Shea, Ciara and Tomlinson, Ryan and Rovin, Brad},
  title = {A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis},
  journal = {Kidney International},
  year = {2026},
  volume = {110},
  number = {2},
  pages = {451--462},
  doi = {10.1016/j.kint.2026.03.030}
}
Kostenlos starten →